ELV earnings analysis — 8-K, guidance, statement tablesElevance Health, Inc. (ELV) 财报解读 — 8-K、guidance、statement tables
Elevance Health (ELV) Q2 2026 Earnings Follow-Up Analysis
1. Consensus Beat Performance: Per the July 15, 2026 official business release and SEC 8-K filing, Q2 2026 adjusted diluted EPS came in at $7.45, 20.6% above the consensus estimate of $6.18, while total revenue hit $49.8B, 2.0% above the $48.8B consensus, both core metrics exceeding market expectations.
2. Revenue and Profitability Quality: GAAP diluted EPS was $6.71, with net income of $1.5B and a 2.9% net margin. Total revenue grew 0.8% YoY, gross margin at 89.1%, operating margin at 4.1% (+13.8% YoY), with EBITDA of $2.1B and a 4.2% margin. Segment-wise, Health Benefits revenue rose 3% YoY but operating margin fell from 3.8% to 2.1% YoY, while Carelon revenue grew 6% YoY with operating margin dipping 0.3pps to 4.9%.
3. Cash Flow and Capital Deployment: Quarterly operating cash flow was $1.9B, capex at $287M, free cash flow at $1.6B. As of June 30, 2026, cash and equivalents totaled $10.2B, total debt $31.0B, net debt $20.8B. The company repurchased 0.7M common shares for $234M and paid a $1.72/share quarterly dividend totaling $373M, with ~$5.3B remaining share repurchase authorization.
4. Guidance Update: The company raised full-year 2026 guidance, with adjusted diluted EPS of at least $27.00 and GAAP diluted EPS of at least $20.10, and raised full-year operating cash flow guidance to at least $6.0B. Management also noted targeted investments to support 2027 adjusted EPS growth of at least 12% off the 2026 earnings baseline.
5. GAAP vs Non-GAAP Reconciliation: The 8-K filing provided GAAP/non-GAAP reconciliation tables on pages 13-14, with adjusted EPS $0.74 higher than GAAP EPS in the quarter, driven by exclusion of one-time below-the-line benefits.
6. Management Commentary: CEO Gail Boudreaux cited disciplined execution and improved cross-portfolio operating performance for the beat, and highlighted investments in medical cost management, member experience, and Carelon integrated solutions.
7. Unresolved Investor Questions: Detailed segment-level profitability breakdowns, full drivers of the YoY increase in days claims payable, full-year capex guidance, and 10-Q filing-specific granular data are not disclosed, and no earnings call transcript is available for additional context.
益维信健康（ELV）2026年第二季度业绩跟进分析
1. 业绩超预期情况：根据公司2026年7月15日发布的官方公告及SEC提交的8-K文件，二季度调整后摊薄EPS为7.45美元，较市场预期的6.18美元高出20.6%；总营收498亿美元，较预期的488亿美元高出2.0%，两项核心指标均超出市场共识。
2. 营收与盈利质量：GAAP摊薄EPS为6.71美元，净利润15亿美元，净利润率2.9%。总营收同比增长0.8%，整体毛利率89.1%，营业利润率4.1%，同比提升13.8%；EBITDA为21亿美元，利润率4.2%。分板块来看，健康福利板块营收同比增长3%，但营业利润率从去年同期的3.8%降至2.1%；Carelon板块营收同比增长6%，营业利润率微降0.3个百分点至4.9%。
3. 现金流与资本运作：季度经营性现金流19亿美元，资本支出2.87亿美元，自由现金流16亿美元。截至6月末，公司现金及等价物102亿美元，总债务310亿美元，净债务208亿美元。季度内公司回购70万股普通股，耗资2.34亿美元，同时派发季度股息每股1.72美元，合计派现3.73亿美元，剩余董事会授权回购额度约53亿美元。
4. 指引更新：公司上调2026全年指引，调整后摊薄EPS至少27.00美元，GAAP摊薄EPS至少20.10美元，同时将全年经营性现金流指引上调至至少60亿美元。管理层还提到将加速相关能力投资，并计划在2026年盈利基础上实现2027年调整后EPS至少12%的增速。
5. GAAP与非GAAP差异：财报披露了两者的调节表，本季度调整后EPS较GAAP EPS高出0.74美元，主要源于一次性线下收益等非经常性项目的剔除。
6. 管理层评论：来自官方公告的CEO盖尔·布德罗的发言提到，业绩超预期源于严谨的执行及多元化业务组合的运营改善，同时强调了医疗成本管理、会员体验等领域的投资。
7. 未明确事项：目前未披露分板块的详细盈利明细、索赔应付账款天数同比变动的完整驱动因素、全年资本支出规划，以及未公开的10-Q文件中的细分业务数据，且暂无业绩电话会纪要可供参考。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。